PLK2

PLK2

A gene on chromosome 5q12.1-q13.2 that encodes a tumour-suppressor serine/threonine-protein kinase involved in synaptic plasticity and memory, centriole duplication and G1/S-phase transition. PLK2 is induced by p53/TP53, suggesting that it may play a role in mitotic checkpoint following stress. It is highly expressed in foetal lung, kidney, spleen and heart.
References in periodicals archive ?
Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is orally administered and has a 24-hour half-life with only mild-to-moderate side effects reported.
Onvansertib targets the PLK1 isoform (not PLK2 or PLK3), is orally available, has a 24-hour drug half-life with only mild to moderate side effects reported.
Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol 2014; 45: 1257-1265, doi: 10.3892/ijo.2014.2516.
Zhao et al., "Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2," International Journal of Oncology, vol.
Several kinases have been linked to [alpha]-synuclein phosphorylation, such as casein kinases 1 and 2 (CK1 and CK2), G protein-coupled receptor kinases 2 and 5 (GRK2 and GRK5), polo-like kinase 2 (PLK2) [29, 72, 73], Fyn [74], and more recently serine/threonine protein kinase (LK6) and MAP kinase-interacting kinase 2a (Mnk2a) [75].
They also observed that miR126 targets the tumour suppressor protein PLK2 (polo-like kinase2) which is involved in the cell cycle checkpoint [64].
Planned LASIK Kamra--two-step implantation (PLK2) can be used to manage patients with both ametropia and presbyopia.
SPAR undergoes activity-dependent phosphorylation-mediated degradation by a serum-inducible serine/threonine kinase (SNK) [28], also known as polo-like kinase 2 (Plk2).
Gene Microarray Q-PCR PLK2 2.2 [+ or -] 0.1 1.8 [+ or -] 0.4 SGK 3.9 [+ or -] 0.2 3.4 [+ or -] 1.5 SE20-4 2.5 [+ or -] 0.2 2.4 [+ or -] 0.2 BHLHB2 2.8 [+ or -] 0.1 4.2 [+ or -] 0.2 CCNL1 3.1 [+ or -] 0.2 2.6 [+ or -] 0.4 C8FW 4.0 [+ or -] 0.2 2.3 [+ or -] 0.2 HES1 8.9 [+ or -] 0.9 1.7 [+ or -] 0.4 FOSB 52 [+ or -] 1.8 2.6 [+ or -] 0.1 DUSP2 17 [+ or -] 0.0 1.7 [+ or -] 0.1 PPP1R15A 4.6 [+ or -] 0.1 0.9 [+ or -] 0.2 NFKB1A 3.7 [+ or -] 0.3 0.9 [+ or -] 0.2 NEU1 2.2 [+ or -] 0.1 1.1 [+ or -] 0.1 DDAH1 -2.2 [+ or -] 0.0 -1.8 [+ or -] 0.1 NFATC1 -2.9 [+ or -] 0.0 -1.8 [+ or -] 0.2 NVKB1 -2.8 [+ or -] 0.0 -5.2 [+ or -] 0.8 Data are mean [+ or -] SD of three independent measurements, which represent fold change on [log.sub.2] scale compared with data obtained from control group.
Onvansertib only targets PLK1 isoform (not PLK2 or PLK3), is oral, has a 24-hour drug half-life with reversible on-target hematologic toxicities.
PCM-075 only targets PLK1 isoform (not PLK2 or PLK3), is oral, and has a 24-hour drug half-life with reversible on-target hematologic toxicities.